Myomo logo
Myomo MYO
$ 1.01 1.0%
report update icon

Quarterly report 2026-Q1
added 05-07-2026

Myomo Cash Flow 2025-2011 | MYO

Brief overview of Myomo's cash movements

The comparison covers five available annual reports between 2021 and 2025.

At the end of the period, operations consumed -$14.5 million rather than generating cash. This profile calls for caution.

Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.

Operating cash flow margin improved from -68.9% to -35.5%. The quality of revenue growth strengthened.

An additional $3.7 million became tied up in estimated working capital, equal to 9% of revenue.

Overall picture

Myomo's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.

Annual Cash Flow Myomo

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-14.5 M -3.29 M -6.17 M -10.2 M -9.55 M -9.03 M -10.3 M -9.61 M -6.15 M -3.2 M - - - - -

Depreciation & Amortization

859 K 206 K 164 K 193 K 146 K 105 K 95.1 K 69.7 K 11.4 K 7.73 K - - - - -

Accounts Payables

1.51 M 1.17 M 1.07 M 570 K 723 K 180 K 450 K 427 K 265 K - - - - - -

Accounts Receivables

4.1 M 3.83 M 2.38 M 1.9 M 1.96 M 925 K 424 K 382 K 297 K - - - - - -

Total Inventories

3.12 M 3.17 M 1.8 M 1.4 M 808 K 707 K 440 K 256 K 201 K - - - - - -

All numbers in USD currency

Quarterly Cash Flow Myomo

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-2.2 M - - -2.68 M - - - -3.25 M - - - -1.82 M - -7.77 M - -2.32 M - -7.72 M - -2.11 M - -7.88 M -6.11 M -2.45 M - -7.7 M -5.41 M -3.12 M - -7.09 M -4.61 M -2.27 M - -4.61 M -2.75 M -1.16 M - -2.3 M -984 K - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

292 K - - 158 K - - - 29.7 K - - - 48.6 K - 144 K - 45.6 K - 95.2 K - 23.3 K - 79.7 K 53 K 26.4 K - 70.7 K 45.1 K 21.6 K - 48.8 K 28.9 K 14.6 K - 6.98 K 4.55 K 2.17 K - 5.86 K 4 K - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

1.81 M 1.62 M 2.51 M 2.49 M 1.17 M 1.3 M 1.37 M 829 K 1.07 M 1.22 M 767 K 907 K 570 K 879 K - 1.01 M 723 K 624 K 612 K 714 K 180 K 180 K 180 K 180 K 450 K 450 K 450 K 450 K 427 K 427 K 427 K 427 K 265 K 265 K 265 K 265 K 311 K - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

4.82 M 5.29 M 7.05 M 4.66 M 3.83 M 3.73 M 2.53 M 1.68 M 2.38 M 2.52 M 1.64 M 1.55 M 1.9 M 1.6 M - 1.69 M 1.96 M 2.22 M 1.13 M 765 K 925 K 925 K 925 K 925 K 424 K 424 K 424 K 424 K 382 K 382 K 382 K 382 K 297 K 297 K 297 K 297 K 115 K 115 K 115 K - - - - - - - - - - - - - - - - - - - - -

Total Inventories

3.55 M 3.65 M 4.13 M 3.37 M 3.17 M 3.38 M 2.6 M 2.39 M 1.8 M 1.48 M 1.34 M 1.57 M 1.4 M 1.48 M - 1.03 M 808 K 644 K 729 K 794 K 707 K 707 K 707 K 707 K 440 K 440 K 440 K 440 K 256 K 256 K 256 K 256 K 201 K 201 K 201 K 201 K 82.4 K 82.4 K 82.4 K - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Myomo, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical devices sector

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
InspireMD InspireMD
NSPR
$ 0.65 -3.68 % $ 41.8 M israelIsrael
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.38 1.79 % $ 223 M canadaCanada
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.48 -1.14 % $ 148 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.4 -2.0 % $ 123 M australiaAustralia
AxoGen AxoGen
AXGN
$ 42.21 2.08 % $ 1.94 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 62.84 -2.33 % $ 9.54 B usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 31.56 -2.46 % $ 27.4 B britainBritain
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 28.17 -0.11 % $ 644 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.73 2.83 % $ 34.3 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.5 2.58 % $ 1.33 B usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.67 -0.77 % $ 454 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.94 2.47 % $ 423 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 11.19 1.08 % $ 463 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Inogen Inogen
INGN
$ 6.45 0.47 % $ 172 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.36 3.08 % $ 22.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.82 -1.39 % $ 13.9 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 121.21 20.18 % $ 4.21 B usaUSA
Beyond Air Beyond Air
XAIR
$ 5.28 -2.68 % $ 43.8 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 -0.6 % $ 60 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.14 -1.12 % $ 4.37 B britainBritain
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA